Pyxis Oncology FY2022 net loss $120.7M; CFO promoted to CFO & COO

Pyxis Oncology, Inc.

Net loss $120.7M ($3.65/share) vs $76.0M ($8.95) in 2021; R&D spend rose to $86.1M from $51.0M.
Cash $180.7M with no debt as of Dec 31, 2022; runway into 1H 2025.
Two Phase 1 trials for PYX-201 and PYX-106 initiated; preliminary data expected late 2023 to early 2024.
CFO Pam Connealy promoted to additional role of COO effective March 22, 2023.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Pamela Connealy

Chief Financial Officer and Chief Operating Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2023-03-22
Filed: March 22, 2023, 7:59 PM ET

On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported the full year ended December 31, 2022 results: net income $120.7 million, EPS ($3.65) per common share.

Period: the full year ended December 31, 2022
Net income: $120.7 million
EPS: ($3.65) per common share
Result: reported results

Exact text from the filing

Net loss was $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022, compared to $76.0 million, or ($8.95) per common share, for the year ended December 31, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Pamela Connealy changed role as Chief Financial Officer and Chief Operating Officer at Pyxis Oncology, Inc..

Action: promoted
Role: Chief Financial Officer and Chief Operating Officer

Exact text from the filing

On March 22, 2023, the Company announced that Pamela Connealy, Chief Financial Officer, has been promoted to the newly created role of Chief Financial Officer and Chief Operating Officer.

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.